表紙:アプタマーの治療薬、技術、およびサービス市場:応用分野別、アプタマータイプ別、標的適応別
市場調査レポート
商品コード
1068655

アプタマーの治療薬、技術、およびサービス市場:応用分野別、アプタマータイプ別、標的適応別

Aptamers: Therapeutics, Technologies and Services Market, Distribution by Application Area (Therapeutics, Research and Diagnostics), Type of Aptamer (DNA, RNA and Peptide), Target Indication (Geographic Atrophy, Macular Degeneration,

出版日: | 発行: Roots Analysis | ページ情報: 英文 350 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=135.61円
アプタマーの治療薬、技術、およびサービス市場:応用分野別、アプタマータイプ別、標的適応別
出版日: 2022年04月07日
発行: Roots Analysis
ページ情報: 英文 350 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

インサイト例

現在、アプタマー技術は、病原体の認識、癌の認識、環境汚染のモニタリング、幹細胞マーカーとして広く利用されており、病気の予防と治療の両方に役立っています。また、COVID-19のパンデミック発生後、COVID-19の検査キットの需要が大幅に増加し、複数の企業がSARS-CoV-2の検出のためのアプタマーベースの診断ツールを開発するようになっています。その結果、業界関係者による様々な取り組みを支援するために、過去5年間で13億米ドル以上の投資が報告されています。

当レポートでは、世界のアプタマーの治療薬、技術、およびサービス市場について調査し、市場の概要とともに、応用分野別、アプタマータイプ別、標的適応別動向、特許、臨床試験動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 序文

第2章 エグゼクティブサマリー

第3章 イントロダクション

  • 章の概要
  • アプタマーのイントロダクション
  • アプタマーの種類
  • アプタマー修飾の必要性
  • アプタマーの利点
  • アプタマーの制限
  • アプタマーの応用
  • 将来予想される動向と機会

第4章 市場概要:治療薬候補

  • 章の概要
  • アプタマーベースの治療法:市場情勢
    • アプタマーの種類別分析
    • 開発段階別分析
    • 治療ライン別分析
    • 投与経路別分析
    • 作用機序別分析
    • 標的適応別分析
    • 治療分野別分析
    • 治療タイプ別分析
  • アプタマーベースの治療法:開発業者の情勢

第5章 市場概要:技術プロバイダー

  • 章の概要
  • アプタマーベースの技術:市場情勢
  • アプタマーベースの技術:開発業者の情勢

第6章 市場概要:サービスプロバイダー

  • 章の概要
  • アプタマーベースのサービスプロバイダー:市場情勢
  • アプタマーベースのサービスプロバイダー:開発業者の情勢

第7章 企業の競争力分析

  • 章の概要
  • 調査手法と主要なパラメータ
  • アプタマーベースのサービスプロバイダー:企業の競争力分析

第8章 技術競争力分析

  • 章の概要
  • 調査手法と主要なパラメータ
  • アプタマーベースのテクノロジープロバイダー

第9章 製品の競争力分析

  • 章の概要
  • 調査手法と主要なパラメータ
  • アプタマーベースの治療法

第10章 パートナーシップとコラボレーション

  • アプタマー治療薬、技術およびサービスプロバイダー:パートナーシップおよびコラボレーションのリスト
  • 2016年~2021年までの年別分析

第11章 資金調達と投資

第12章 助成金分析

第13章 出版物の分析

第14章 特許分析

第15章 臨床試験分析

第16章 新興企業動向

第17章 企業プロファイル

  • 章の概要
  • Ajinomoto Bio-Pharma Services
  • BioSpring
  • CliniSciences
  • New England Biolabs
  • LGC Biosearch Technologies
  • Nitto Denko Avecia
  • CMIC Group

第18章 技術企業プロファイル

  • 章の概要
  • SomaLogic
  • NOXXON Pharma
  • RIBOMIC
  • Halo-Bio RNAi Therapeutics
  • NeuroNeuro

第19章 需要分析

第20章 市場予測と機会分析

第21章 結論

第22章 付録I:集計データ

第23章 付録II:企業と組織のリスト

図表

List Of Figures

  • Figure 2.1: Executive Summary: Overall Market Landscape
  • Figure 2.2: Executive Summary: Partnerships and Collaborations
  • Figure 2.3: Executive Summary: Funding and Investments
  • Figure 2.4: Executive Summary: Grants Analysis
  • Figure 2.5: Executive Summary: Publication Analysis
  • Figure 2.6: Executive Summary: Patent Analysis
  • Figure 2.7: Executive Summary: Clinical Trial Analysis
  • Figure 2.8: Executive Summary: Demand Analysis
  • Figure 2.9: Executive Summary: Market Forecast
  • Figure 3.1: Evolution of SELEX
  • Figure 3.2: Process of Synthesizing DNA Aptamers
  • Figure 3.3: Process of Synthesizing RNA Aptamers
  • Figure 3.4: Types of Aptamer Modifications
  • Figure 3.5: Applications of Aptamers
  • Figure 4.1: Aptamer-based Therapeutics: Distribution by Type of Aptamer
  • Figure 4.2: Aptamer-based Therapeutics: Distribution by Phase of Development
  • Figure 4.3: Aptamer-based Therapeutics: Distribution by Line of Treatment
  • Figure 4.4: Aptamer-based Therapeutics: Distribution by Route of Administration
  • Figure 4.5: Aptamer-based Therapeutics: Distribution by Mechanism of Action
  • Figure 4.6: Aptamer-based Therapeutics: Distribution by Target Indication
  • Figure 4.7: Aptamer-based Therapeutics: Distribution by Therapeutic Area
  • Figure 4.8: Aptamer-based Therapeutics: Distribution by Type of Therapy
  • Figure 4.9: Aptamer-based Therapeutics Developers: Distribution by Year of Establishment
  • Figure 4.10: Aptamer-based Therapeutics Developers: Distribution by Company Size
  • Figure 4.11: Aptamer-based Therapeutics Developers: Distribution by Location of Headquarters
  • Figure 4.12: Aptamer-based Therapeutics Developers: Distribution by Company Size and Location of Headquarters
  • Figure 4.13: Most Active Players: Distribution by Number of Therapies
  • Figure 5.1: Aptamer-based Technologies: Distribution by Type of Aptamer
  • Figure 5.2: Aptamer-based Technologies: Distribution by Status of Development
  • Figure 5.3: Aptamer-based Technologies: Distribution by Application Area
  • Figure 5.4: Aptamer-based Technologies: Distribution by Type of Technology Used
  • Figure 5.5: Aptamer-based Technologies: Distribution by Purpose of Technology
  • Figure 5.6: Aptamer-based Technologies: Distribution by Type of Analyte
  • Figure 5.7: Aptamer-based Technologies: Distribution by Therapeutic Area
  • Figure 5.8: Aptamer-based Technologies: Distribution by Target Indication
  • Figure 5.9: Aptamer-based Technologies: Distribution by Application Area, Purpose of Technology and Region
  • Figure 5.9: Aptamer-based Technology Providers Distribution by Year of Establishment
  • Figure 5.10: Aptamer-based Technology Providers: Distribution by Company Size
  • Figure 5.11: Aptamer-based Technology Providers: Distribution by Location of Headquarters
  • Figure 5.12: Aptamer-based Technology Providers: Distribution by Company Size and Location of Headquarters
  • Figure 6.1: Aptamer-based Service Providers: Distribution by Type of Service Provider
  • Figure 6.2: Aptamer-based Service Providers: Distribution by Scale of Operation
  • Figure 6.3: Aptamer-based Service Providers: Distribution by Application Area
  • Figure 6.4: Aptamer-based Service Providers: Distribution by Type of Technology Used
  • Figure 6.5: Aptamer-based Service Providers: Distribution by Type of Technology Platform
  • Figure 6.6: Aptamer-based Service Providers: Distribution by Types of Analysis Offered
  • Figure 6.7: Aptamer-based Service Providers: Distribution by Type of Service Provider, Type of Analysis Offered and Region
  • Figure 6.8: Aptamer-based Service Providers: Distribution by Year of Establishment
  • Figure 6.9: Aptamer-based Service Providers: Distribution by Company Size
  • Figure 6.10: Aptamer-based Service Providers: Distribution by Location of Headquarters
  • Figure 6.11: Aptamer-based Service Providers: Distribution by Company Size and Location of Headquarters
  • Figure 7.1: Company Competitiveness Analysis: Very Small Companies (Peer Group 1)
  • Figure 7.2: Company Competitiveness Analysis: Small Companies (Peer Group 2)
  • Figure 7.3: Company Competitiveness Analysis: Mid-sized Companies (Peer Group 3)
  • Figure 7.4: Company Competitiveness Analysis: Large Companies (Peer Group 4)
  • Figure 7.5: Company Competitiveness Analysis: Very Large Companies (Peer Group 5)
  • Figure 8.1: Technology Competitiveness Analysis: Very Small Companies (Peer Group 1)
  • Figure 8.2: Technology Competitiveness Analysis: Small Companies (Peer Group 2)
  • Figure 8.3: Technology Competitiveness Analysis: Mid-sized Companies (Peer Group 3)
  • Figure 8.4: Technology Competitiveness Analysis: Large Companies (Peer Group 4)
  • Figure 8.5: Technology Competitiveness Analysis: Very Large Companies (Peer Group 5)
  • Figure 9.1: Product Competitiveness Analysis: Very Small Companies (Peer Group 1)
  • Figure 9.2: Product Competitiveness Analysis: Small Companies (Peer Group 2)
  • Figure 9.3: Product Competitiveness Analysis: Mid-sized Companies (Peer Group 3)
  • Figure 9.4: Product Competitiveness Analysis: Large Companies (Peer Group 4)
  • Figure 9.5: Product Competitiveness Analysis: Very Large Companies (Peer Group 5)
  • Figure 10.1: Partnerships and Collaborations: Cumulative Year-wise Distribution, 2016-2021
  • Figure 10.2: Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 10.3: Partnerships and Collaborations: Distribution by Year and Type of Partnership
  • Figure 10.4: Partnerships and Collaborations: Distribution by Type of Partner
  • Figure 10.5: Partnerships and Collaborations: Distribution by Year and Type of Partner
  • Figure 10.6: Partnerships and Collaborations: Distribution by Type of Partnership and Partner
  • Figure 10.7: Partnerships and Collaborations: Distribution by Focus Area
  • Figure 10.8: Most Active Players: Distribution by Number of Partnerships
  • Figure 10.9: Partnerships and Collaborations: Distribution by Region (Continent-wise)
  • Figure 10.10: Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
  • Figure 10.11: Partnerships and Collaborations: Distribution by Region (Country-wise)
  • Figure 10.12: Partnerships and Collaborations: Local and International Agreements
  • Figure 11.1: Funding and Investments: Cumulative Distribution of Instances by Year, 2016-2021
  • Figure 11.2: Funding and Investments: Distribution of Instances by Type of Funding
  • Figure 11.3: Funding and Investments: Distribution of Instances by Year and Type of Funding, 2016-2021
  • Figure 11.4: Funding and Investments: Cumulative Distribution of Amount Invested by Year, 2016-2021
  • Figure 11.5: Funding and Investments: Distribution of Amount Invested by Type of Funding
  • Figure 11.6: Funding and Investments: Distribution of Amount Invested by Year and Type of Funding, 2016-2021
  • Figure 11.7: Funding and Investments: Distribution of Instances by Region
  • Figure 11.8: Funding and Investments: Distribution of Total Amount Invested by Region
  • Figure 11.9: Most Active Players: Distribution by Number of Instances
  • Figure 11.10: Most Active Players: Distribution by Amount Raised
  • Figure 11.11: Most Active Investors: Distribution by Number of Instances
  • Figure 12.1: Grant Analysis: Cumulative Year-wise Trend, 2016-2021
  • Figure 12.2: Grant Analysis: Distribution by Grant Amount
  • Figure 12.3: Grant Analysis: Distribution by Activity Code
  • Figure 12.4: Grant Analysis: Distribution by Support Period
  • Figure 12.5: Grant Analysis: Distribution by Purpose of Grant
  • Figure 12.6: Grant Analysis: Distribution by Type of Grant
  • Figure 12.7: Grant Analysis: Distribution by Funding Institute and Support Period
  • Figure 12.8: Grant Analysis: Distribution by Type of Organization
  • Figure 12.9: Most Popular Recipient Organization: Distribution by Number of Instances
  • Figure 12.10: Most Popular Recipient Organization: Distribution by Amount Granted
  • Figure 12.11: Most Popular Recipient Organization: Distribution in US
  • Figure 12.12: Prominent Program Officers: Distribution by Number of Grants
  • Figure 12.13: Academic Grant Analysis: Distribution by Study Section
  • Figure 12.14: Academic Grant Analysis: Distribution by Most Popular Department
  • Figure 12.15: Academic Grant Analysis: Distribution of Popular NIH Spending Categories
  • Figure 13.1: Publication Analysis: Quarterly Trend of Publications (2021)
  • Figure 13.2: Publication Analysis: Distribution by Type of Publication
  • Figure 13.3: Most Prominent Journals: Distribution by Number of Publications
  • Figure 13.4: Most Prominent Authors: Distribution by Number of Publications
  • Figure 13.5: Most Popular Publishers: Distribution by Number of Publications
  • Figure 13.6: Most Popular Copyright Holders: Distribution by Number of Publications
  • Figure 13.7: Most Popular Keywords: Distribution by Number of Publications
  • Figure 13.8: Publication Analysis: Distribution by Affiliation
  • Figure 13.9: Publication Analysis: Distribution by Affiliation and Geography
  • Figure 13.10: Publication Analysis: Distribution by Funding Institute
  • Figure 14.1: Patent Analysis: Distribution by Type of Patent
  • Figure 14.2: Patent Analysis: Distribution by Granted Patents
  • Figure 14.3: Patent Analysis: Distribution by Publication Year
  • Figure 14.4: Patent Analysis: Year-wise Trend of Filed Patent Applications
  • Figure 14.5: Patent Analysis: Distribution by Issuing Authority
  • Figure 14.6: Patent Analysis: Distribution by Focus Area
  • Figure 14.7: Patent Analysis: Distribution by Patent Age
  • Figure 14.8: Patent Analysis: Distribution by CPC Symbols
  • Figure 14.9: Patent Analysis: Distribution by Type of Applicant
  • Figure 14.10: Leading Players: Distribution by Number of Patents
  • Figure 15.1: Clinical Trial Analysis: Distribution by Trial Status
  • Figure 15.2: Clinical Trial Analysis: Distribution by Trial Registration Year
  • Figure 15.3: Clinical Trial Analysis: Distribution by Trial Status and Trial Registration Year
  • Figure 15.4: Clinical Trial Analysis: Distribution by Number of Patients Enrolled and Phase of Development
  • Figure 15.5: Clinical Trial Analysis: Distribution by Type of Sponsor
  • Figure 15.6: Clinical Trial Analysis: Distribution by Target Patient Segment
  • Figure 15.7: Clinical Trial Analysis: Distribution by Study Design
  • Figure 15.8: Clinical Trial Analysis: Distribution by Type of Masking
  • Figure 15.9: Clinical Trial Analysis: Distribution by Type of Interventional Model
  • Figure 15.10: Clinical Trial Analysis: Distribution by Primary Purpose of Trial
  • Figure 15.11: Clinical Trial Analysis: Distribution of Enrolled Patient Population by Geography
  • Figure 16.1: Start-up Health Indexing: Distribution by Number of Technologies
  • Figure 16.2: Start-up Health Indexing: Distribution by Type of Aptamer
  • Figure 16.3: Start-up Health Indexing: Distribution by Status of Development
  • Figure 16.4: Start-up Health Indexing: Distribution by Area of Application
  • Figure 16.5: Start-up Health Indexing: Distribution by Type of Bioanalytical Technology Used
  • Figure 16.6: Start-up Health Indexing: Distribution by Technology Application Area
  • Figure 16.7: Start-up Health Indexing: Distribution by Patent Count
  • Figure 16.8: Start-up Health Indexing: Roots Analysis Perspective
  • Figure 19.1: Demand Analysis: Global Demand for Aptamers
  • Figure 19.2: Demand Analysis: Distribution by Scale of Operation
  • Figure 19.3: Demand Analysis: Clinical Demand for Aptamers
  • Figure 19.4: Demand Analysis: Commercial Demand for Aptamers
  • Figure 19.5: Demand Analysis: Distribution by Region
  • Figure 19.6: Demand Analysis: Demand for Aptamers in North America
  • Figure 19.7: Demand Analysis: Demand for Aptamers in Europe
  • Figure 19.8: Demand Analysis: Demand for Aptamers in Asia-Pacific
  • Figure 20.1: Global Aptamer Therapeutics, Technologies and Services Market, 2022-2035
  • Figure 20.2: Aptamer Therapeutics Market, 2022-2035
  • Figure 20.3: Aptamer Therapeutics Market: Distribution by Type of Aptamer, 2022-2035
  • Figure 20.4: Aptamer Therapeutics Market for DNA Aptamers, 2022-2035
  • Figure 20.5: Aptamer Therapeutics Market for RNA Aptamers, 2022-2035
  • Figure 20.6: Aptamer Therapeutics Market for L-RNA Aptamers, 2022-2035
  • Figure 20.7: Aptamer Therapeutics Market: Distribution by Target Indication, 2022-2035
  • Figure 20.8: Aptamer Therapeutics Market for Brain Cancer, 2022-2035
  • Figure 20.9: Aptamer Therapeutics Market for Geographic Atrophy, 2022-2035
  • Figure 20.10: Aptamer Therapeutics Market for Hemophilia A, 2022-2035
  • Figure 20.11: Aptamer Therapeutics Market for Macular Degeneration, 2022-2035
  • Figure 20.12: Aptamer Therapeutics Market for Pancreatic Cancer, 2022-2035
  • Figure 20.13: Aptamer Therapeutics Market for Von Willebrand Diseases, 2022-2035
  • Figure 20.14: Aptamer Therapeutics Market: Distribution by Route of Administration, 2022-2035
  • Figure 20.15: Aptamer Therapeutics Market for Intravenous Route, 2022-2035
  • Figure 20.16: Aptamer Therapeutics Market for Intravitreal Route, 2022-2035
  • Figure 20.17: Aptamer Therapeutics Market for Subcutaneous Route, 2022-2035
  • Figure 20.18: Aptamer Therapeutics Market: Distribution by Geography, 2022-2035
  • Figure 20.19: Aptamer Therapeutics Market in North America, 2022-2035
  • Figure 20.20: Aptamer Therapeutics Market in Europe, 2022-2035
  • Figure 20.21: Aptamer Therapeutics Market in Asia-Pacific, 2022-2035
  • Figure 20.22: Aptamer Therapeutics Market in Rest of the World, 2022-2035
  • Figure 20.23: Aptamer Technologies Market, 2022-2035
  • Figure 20.24: Aptamer Technologies Market: Distribution by Focus Area, 2022-2035
  • Figure 20.25: Aptamer Technologies Market for Product Development Initiatives, 2022-2035
  • Figure 20.26: Aptamer Technologies Market for Product Commercialization Initiatives, 2022-2035
  • Figure 20.27: Aptamer Technologies Market for Technology Integration Initiatives, 2022-2035
  • Figure 20.28: Aptamer Technologies Market for Technology Utilization Initiatives, 2022-2035
  • Figure 20.29: Aptamer Technologies Market for Other Initiatives, 2022-2035
  • Figure 20.30: Aptamer Technologies Market: Distribution by Company Size, 2022-2035
  • Figure 20.31: Aptamer Technologies Market for Very Small Companies, 2022-2035
  • Figure 20.32: Aptamer Technologies Market for Small Companies, 2022-2035
  • Figure 20.33: Aptamer Technologies Market for Mid-sized Companies, 2022-2035
  • Figure 20.34: Aptamer Technologies Market for Large Companies, 2022-2035
  • Figure 20.35: Aptamer Technologies Market for Very Large Companies, 2022-2035
  • Figure 20.36: Aptamer Technologies Market: Distribution by Geography, 2022-2035
  • Figure 20.37: Aptamer Technologies Market in North America, 2022-2035
  • Figure 20.38: Aptamer Technologies Market in Europe, 2022-2035
  • Figure 20.39: Aptamer Technologies Market in Asia-Pacific, 2022-2035
  • Figure 20.40: Aptamer Services Market, 2022-2035
  • Figure 20.41: Aptamer Services Market: Distribution by Scale of Operation, 2022-2035
  • Figure 20.42: Aptamer Services Market for Small Scale Operations, 2022-2035
  • Figure 20.43: Aptamer Services Market for Medium-Scale Operations, 2022-2035
  • Figure 20.44: Aptamer Services Market for Large Scale Operations, 2022-2035
  • Figure 20.45: Aptamer Services Market: Distribution by Geography, 2022-2035
  • Figure 20.46: Aptamer Services Market in North America, 2022-2035
  • Figure 20.47: Aptamer Services Market in Europe, 2022-2035
  • Figure 20.48: Aptamer Services Market in Asia-Pacific, 2022-2035
  • Figure 21.1: Concluding Remarks: Overall Market Landscape
  • Figure 21.2: Concluding Remarks: Partnerships and Collaborations
  • Figure 21.3: Concluding Remarks: Funding and Investments
  • Figure 21.4: Concluding Remarks: Grants Analysis
  • Figure 21.5: Concluding Remarks: Publication Analysis
  • Figure 21.6: Concluding Remarks: Patent Analysis
  • Figure 21.7: Concluding Remarks: Clinical Trial Analysis
  • Figure 21.8: Concluding Remarks: Demand Analysis
  • Figure 21.9: Concluding Remarks: Market Forecast

List Of Tables

  • Table 3.1: Key Characteristics: Aptamers versus Antibodies
  • Table 3.2: Comparison of DNA, RNA and Peptide Aptamers
  • Table 4.1: Aptamer-based Therapeutics: Information on Phase of Development, Type of Aptamer, Target Indication and Therapeutic Area
  • Table 4.2: Aptamer-based Therapeutics: Information on Line of Treatment, Route of Administration, Mechanism of Action and Type of Therapy
  • Table 4.3: List of Aptamer-based Therapeutic Developers
  • Table 5.1: Aptamer-based Technologies: Information on Status of Development and Type of Aptamer
  • Table 5.2: Aptamer-based Technologies: Information on Application Area, Type of Technology
  • Table 5.3: Aptamer-based Technologies: Information on Purpose of Technology and Type of Analyte Needed
  • Table 5.4: List of Aptamer-based Technology Developers
  • Table 6.1: Aptamer-based Technology Providers: Information on Type of Service Provider, Scale of Operation and Application Area
  • Table 6.2: Aptamer-based Technology Providers: Information on Technology Used for Analysis and Analysis Offered
  • Table 6.3: List of Aptamer-based Service Providers
  • Table 10.1: Aptamer Therapeutics, Technologies and Service Providers: List of Partnerships and Collaborations
  • Table 11.1: Aptamer Therapeutics, Technologies and Service Providers: List of Funding and Investments
  • Table 12.1: Aptamer Therapeutics, Technologies and Service Providers: List of Academic Grants
  • Table 13.1: Aptamer Therapeutics, Technologies and Service Providers: List of Publications
  • Table 15.3: Aptamer-based Therapeutics: List of Clinical Trials
  • Table 17.1: Ajinomoto Bio-Pharma Services: Key Highlights
  • Table 17.2: Ajinomoto Bio-Pharma Services: Service Portfolio
  • Table 17.3: Ajinomoto Bio-Pharma Services: Recent Developments and Future Outlook
  • Table 17.4: BioSpring: Key Highlights
  • Table 17.5: BioSpring: Service Portfolio
  • Table 17.6: CliniSciences: Key Highlights
  • Table 17.7: New England Biolabs: Key Highlights
  • Table 17.8: New England Biolabs: Product Portfolio
  • Table 17.9: New England Biolabs: Recent Developments and Future Outlook
  • Table 17.10: Biosearch Technologies: Key Highlights
  • Table 17.11: Biosearch Technologies: Service Portfolio
  • Table 17.12: Biosearch Technologies: Manufacturing Facilities and Capabilities
  • Table 17.13: Biosearch Technologies: Recent Developments and Future Outlook
  • Table 17.14: Nitto Denko Avecia: Key Highlights
  • Table 17.15: Nitto Denko Avecia: Recent Developments and Future Outlook
  • Table 17.16: CMIC Group: Key Highlights
  • Table 17.17: CMIC Group: Recent Developments and Future Outlook
  • Table 18.1: SomaLogic: Recent Developments and Future Outlook
  • Table 18.2: NOXXON Pharma: Recent Developments and Future Outlook
  • Table 18.3: RIBOMIC: Recent Developments and Future Outlook
  • Table 21.1: Concluding Remarks: Overall Market Landscape
  • Table 21.2: Concluding Remarks: Partnerships and Collaborations
  • Table 21.3: Concluding Remarks: Funding and Investments
  • Table 21.4: Concluding Remarks: Grants Analysis
  • Table 21.5: Concluding Remarks: Publication Analysis
  • Table 21.6: Concluding Remarks: Patent Analysis
  • Table 21.7: Concluding Remarks: Clinical Trial Analysis
  • Table 21.8: Concluding Remarks: Demand Analysis
  • Table 21.9: Concluding Remarks: Market Forecast
  • Table 22.1: Aptamer-based Therapeutics: Distribution by Type of Aptamer
  • Table 22.1: Aptamer-based Therapeutics: Distribution by Type of Aptamer
  • Table 22.2: Aptamer-based Therapeutics: Distribution by Phase of Development
  • Table 22.3: Aptamer-based Therapeutics: Distribution by Line of Treatment
  • Table 22.4: Aptamer-based Therapeutics: Distribution by Route of Administration
  • Table 22.5: Aptamer-based Therapeutics: Distribution by Mechanism of Action
  • Table 22.6: Aptamer-based Therapeutics: Distribution by Target Indication
  • Table 22.7: Aptamer-based Therapeutics: Distribution by Therapeutic Area
  • Table 22.8: Aptamer-based Therapeutics: Distribution by Type of Therapy
  • Table 22.9: Aptamer-based Therapeutics Developers: Distribution by Year of Establishment
  • Table 22.10: Aptamer-based Therapeutics Developers: Distribution by Company Size
  • Table 22.11: Aptamer-based Therapeutics Developers: Distribution by Location of Headquarters
  • Table 22.12: Aptamer-based Therapeutics Developers: Distribution by Company Size and Location of Headquarters
  • Table 22.13: Most Active Players: Distribution by Number of Therapies
  • Table 22.14: Aptamer-based Technologies: Distribution by Type of Aptamer
  • Table 22.15: Aptamer-based Technologies: Distribution by Status of Development
  • Table 22.16: Aptamer-based Technologies: Distribution by Application Area
  • Table 22.17: Aptamer-based Technologies: Distribution by Type of Technology Used
  • Table 22.18: Aptamer-based Technologies: Distribution by Purpose of Technology
  • Table 22.19: Aptamer-based Technologies: Distribution by Type of Analyte
  • Table 22.20: Aptamer-based Technologies: Distribution by Therapeutic Area
  • Table 22.21: Aptamer-based Technologies: Distribution by Target Indication
  • Table 22.22: Aptamer-based Technologies: Distribution by Application Area, Purpose of Technology and Region
  • Table 22.23: Aptamer-based Technology Providers Distribution by Year of Establishment
  • Table 22.24: Aptamer-based Technology Providers: Distribution by Company Size
  • Table 22.25: Aptamer-based Technology Providers: Distribution by Location of Headquarters
  • Table 22.26: Aptamer-based Technology Providers: Distribution by Company Size and Location of Headquarters
  • Table 22.27: Aptamer-based Service Providers: Distribution by Type of Service Provider
  • Table 22.28: Aptamer-based Service Providers: Distribution by Scale of Operation
  • Table 22.29: Aptamer-based Service Providers: Distribution by Application Area
  • Table 22.30: Aptamer-based Service Providers: Distribution by Type of Technology Used
  • Table 22.31: Aptamer-based Service Providers: Distribution by Type of Technology Platform
  • Table 22.32: Aptamer-based Service Providers: Distribution by Types of Analysis Offered
  • Table 22.33: Aptamer-based Service Providers: Distribution by Type of Service Provider, Type of Analysis Offered and Region
  • Table 22.34: Aptamer-based Service Providers: Distribution by Year of Establishment
  • Table 22.35: Aptamer-based Service Providers: Distribution by Company Size
  • Table 22.36: Aptamer-based Service Providers: Distribution by Location of Headquarters
  • Table 22.37: Aptamer-based Service Providers: Distribution by Company Size and Location of Headquarters
  • Table 22.38: Partnerships and Collaborations: Cumulative Year-wise Distribution, 2016-2021
  • Table 22.39: Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 22.40: Partnerships and Collaborations: Distribution by Year and Type of Partnership
  • Table 22.41: Partnerships and Collaborations: Distribution by Type of Partner
  • Table 22.42: Partnerships and Collaborations: Distribution by Year and Type of Partner
  • Table 22.43: Partnerships and Collaborations: Distribution by Type of Partnership and Partner
  • Table 22.44: Partnerships and Collaborations: Distribution by Focus Area
  • Table 22.45: Most Active Players: Distribution by Number of Partnerships
  • Table 22.46: Partnerships and Collaborations: Distribution by Region (Continent-wise)
  • Table 22.47: Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
  • Table 22.48: Partnerships and Collaborations: Distribution by Region (Country-wise)
  • Table 22.49: Partnerships and Collaborations: Local and International Agreements
  • Table 22.50: Funding and Investments: Cumulative Distribution of Instances by Year, 2016-2021
  • Table 22.51: Funding and Investments: Distribution of Instances by Type of Funding
  • Table 22.52: Funding and Investments: Distribution of Instances by Year and Type of Funding, 2016-2021
  • Table 22.53: Funding and Investments: Cumulative Distribution of Amount Invested by Year, 2016-2021
  • Table 22.54: Funding and Investments: Distribution of Amount Invested by Type of Funding
  • Table 22.55: Funding and Investments: Distribution of Amount Invested by Year and Type of Funding, 2016-2021
  • Table 22.56: Funding and Investments: Distribution of Instances by Region
  • Table 22.57: Funding and Investments: Distribution of Total Amount Invested by Region
  • Table 22.58: Most Active Players: Distribution by Number of Instances
  • Table 22.59: Most Active Players: Distribution by Amount Raised
  • Table 22.60: Most Active Investors: Distribution by Number of Instances
  • Table 22.61: Grant Analysis: Cumulative Year-wise Trend, 2016-2021
  • Table 22.62: Grant Analysis: Distribution by Grant Amount
  • Table 22.63: Grant Analysis: Distribution by Activity Code
  • Table 22.64: Grant Analysis: Distribution by Support Period
  • Table 22.65: Grant Analysis: Distribution by Purpose of Grant
  • Table 22.66: Grant Analysis: Distribution by Type of Grant
  • Table 22.67: Grant Analysis: Distribution by Funding Institute and Support Period
  • Table 22.68: Grant Analysis: Distribution by Type of Organization
  • Table 22.69: Most Popular Recipient Organization: Distribution by Number of Instances
  • Table 22.70: Most Popular Recipient Organization: Distribution by Amount Granted
  • Table 22.71: Most Popular Recipient Organization: Distribution in US
  • Table 22.72: Prominent Program Officers: Distribution by Number of Grants
  • Table 22.73: Academic Grant Analysis: Distribution by Study Section
  • Table 22.74: Academic Grant Analysis: Distribution by Most Popular Department
  • Table 22.75: Publication Analysis: Quarterly Trend of Publications (2021)
  • Table 22.76: Publication Analysis: Distribution by Type of Publication
  • Table 22.77: Most Prominent Journals: Distribution by Number of Publications
  • Table 22.78: Most Prominent Authors: Distribution by Number of Publications
  • Table 22.79: Most Popular Publishers: Distribution by Number of Publications
  • Table 22.80: Most Popular Copyright Holders: Distribution by Number of Publications
  • Table 22.81: Most Popular Keywords: Distribution by Number of Publications
  • Table 22.82: Publication Analysis: Distribution by Affiliation
  • Table 22.83: Publication Analysis: Distribution by Affiliation and Geography
  • Table 22.84: Publication Analysis: Distribution by Funding Institute
  • Table 22.85: Patent Analysis: Distribution by Type of Patent
  • Table 22.86: Patent Analysis: Distribution by Granted Patents
  • Table 22.87: Patent Analysis: Distribution by Publication Year
  • Table 22.88: Patent Analysis: Year-wise Trend of Filed Patent Applications
  • Table 22.89: Patent Analysis: Distribution by Issuing Authority
  • Table 22.90: Patent Analysis: Distribution by Patent Focus Area
  • Table 22.91: Patent Analysis: Distribution by Patent Age
  • Table 22.92: Patent Analysis: Distribution by CPC Symbols
  • Table 22.93: Patent Analysis: Distribution by Type of Applicant
  • Table 22.94: Leading Players: Distribution by Number of Patents
  • Table 22.95: Clinical Trial Analysis: Distribution by Trial Status
  • Table 22.96: Clinical Trial Analysis: Distribution by Trial Registration Year
  • Table 22.97: Clinical Trial Analysis: Distribution by Trial Status and Trial Registration Year
  • Table 22.98: Clinical Trial Analysis: Distribution by Number of Patients Enrolled and Phase of Development
  • Table 22.99: Clinical Trial Analysis: Distribution by Type of Sponsor
  • Table 22.100: Clinical Trial Analysis: Distribution by Target Patient Segment
  • Table 22.101: Clinical Trial Analysis: Distribution by Study Design
  • Table 22.102: Clinical Trial Analysis: Distribution by Type of Masking
  • Table 22.103: Clinical Trial Analysis: Distribution by Type of Interventional Model
  • Table 22.104: Clinical Trial Analysis: Distribution by Primary Purpose of Trial
  • Table 22.105: Clinical Trial Analysis: Distribution of Enrolled Patient Population by Geography
  • Table 22.106: Start-up Health Indexing: Distribution by Number of Technologies
  • Table 22.107: Start-up Health Indexing: Distribution by Type of Aptamer
  • Table 22.108: Start-up Health Indexing: Distribution by Status of Development
  • Table 22.109: Start-up Health Indexing: Distribution by Area of Application
  • Table 22.110: Start-up Health Indexing: Distribution by Type of Bioanalytical Technology Used
  • Table 22.111: Start-up Health Indexing: Distribution by Technology Application Area
  • Table 22.112: Start-up Health Indexing: Distribution by Patent Count
  • Table 22.113: Start-up Health Indexing: Roots Analysis Perspective
  • Table 22.114: Demand Analysis: Global Demand for Aptamers
  • Table 22.115: Demand Analysis: Distribution by Scale of Operation
  • Table 22.116: Demand Analysis: Clinical Demand for Aptamers
  • Table 22.117: Demand Analysis: Commercial Demand for Aptamers
  • Table 22.118: Demand Analysis: Distribution by Region
  • Table 22.119: Demand Analysis: Demand for Aptamers in North America
  • Table 22.120: Demand Analysis: Demand for Aptamers in Europe
  • Table 22.121: Demand Analysis: Demand for Aptamers in Asia-Pacific
  • Table 22.122: Global Aptamer Therapeutics, Technologies and Services Market, 2022-2035
  • Table 22.123: Aptamer Therapeutics Market, 2022-2035
  • Table 22.124: Aptamer Therapeutics Market: Distribution by Type of Aptamer, 2022-2035
  • Table 22.125: Aptamer Therapeutics Market for DNA Aptamers, 2022-2035
  • Table 22.126: Aptamer Therapeutics Market for RNA Aptamers, 2022-2035
  • Table 22.127: Aptamer Therapeutics Market for L-RNA Aptamers, 2022-2035
  • Table 22.128: Aptamer Therapeutics Market: Distribution by Target Indication, 2022-2035
  • Table 22.129: Aptamer Therapeutics Market for Brain Cancer, 2022-2035
  • Table 22.130: Aptamer Therapeutics Market for Geographic Atrophy, 2022-2035
  • Table 22.131: Aptamer Therapeutics Market for Hemophilia A, 2022-2035
  • Table 22.132: Aptamer Therapeutics Market for Macular Degeneration, 2022-2035
  • Table 22.133: Aptamer Therapeutics Market for Pancreatic Cancer, 2022-2035
  • Table 22.134: Aptamer Therapeutics Market for Von Willebrand Diseases, 2022-2035
  • Table 22.135: Aptamer Therapeutics Market: Distribution by Route of Administration, 2022-2035
  • Table 22.136: Aptamer Therapeutics Market for Intravenous Route, 2022-2035
  • Table 22.137: Aptamer Therapeutics Market for Intravitreal Route, 2022-2035
  • Table 22.138: Aptamer Therapeutics Market for Subcutaneous Route, 2022-2035
  • Table 22.139: Aptamer Therapeutics Market: Distribution by Geography, 2022-2035
  • Table 22.140: Aptamer Therapeutics Market in North America, 2022-2035
  • Table 22.141: Aptamer Therapeutics Market in Europe, 2022-2035
  • Table 22.142: Aptamer Therapeutics Market in Asia-Pacific, 2022-2035
  • Table 22.143: Aptamer Therapeutics Market in Rest of the World, 2022-2035
  • Table 22.144: Aptamer Technologies Market, 2022-2035
  • Table 22.145: Aptamer Technologies Market: Distribution by Focus Area, 2022-2035
  • Table 22.146: Aptamer Technologies Market for Product Development Initiatives, 2022-2035
  • Table 22.147: Aptamer Technologies Market for Product Commercialization Initiatives, 2022-2035
  • Table 22.148: Aptamer Technologies Market for Technology Integration Initiatives, 2022-2035
  • Table 22.149: Aptamer Technologies Market for Technology Utilization Initiatives, 2022-2035
  • Table 22.150: Aptamer Technologies Market for Other Initiatives, 2022-2035
  • Table 22.151: Aptamer Technologies Market: Distribution by Company Size, 2022-2035
  • Table 22.152: Aptamer Therapeutics Market for Very Small Companies, 2022-2035
  • Table 22.153: Aptamer Technologies Market for Small Companies, 2022-2035
  • Table 22.154: Aptamer Technologies Market for Mid-sized Companies, 2022-2035
  • Table 22.155: Aptamer Technologies Market for Large Companies, 2022-2035
  • Table 22.156: Aptamer Technologies Market for Very Large Companies, 2022-2035
  • Table 22.157: Aptamer Technologies Market: Distribution by Geography, 2022-2035
  • Table 22.158: Aptamer Technologies Market in North America, 2022-2035
  • Table 22.159: Aptamer Technologies Market in Europe, 2022-2035
  • Table 22.160: Aptamer Technologies Market in Asia-Pacific, 2022-2035
  • Table 22.161: Aptamer Services Market, 2022-2035
  • Table 22.162: Aptamer Services Market: Distribution by Scale of Operation, 2022-2035
  • Table 22.163: Aptamer Services Market for Small Scale Operations, 2022-2035
  • Table 22.164: Aptamer Services Market for Medium-Scale Operations, 2022-2035
  • Table 22.165: Aptamer Services Market for Large Scale Operations, 2022-2035
  • Table 22.166: Aptamer Services Market: Distribution by Geography, 2022-2035
  • Table 22.167: Aptamer Services Market in North America, 2022-2035
  • Table 22.168: Aptamer Services Market in Europe, 2022-2035
  • Table 22.169: Aptamer Services Market in Asia-Pacific, 2022-2035

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  • 1. 2bind
  • 2. Accelero ® Bioanalytics
  • 3. Achiko
  • 4. Acuitas Capital
  • 5. Admera Health
  • 6. Aju IB
  • 7. Allergan
  • 8. Amgen
  • 9. ASKA Pharmaceutical
  • 10. AstraZeneca
  • 11. blueconic
  • 12. Casdin Capital
  • 13. deCODE genetics (A Subsidiary of Amgen)
  • 14. DeepVerge
  • 15. Drive Therapeutics
  • 16. EIT Health
  • 17. Engineering and Physical Sciences Research Council (EPSRC)
  • 18. Epsilon Molecular Engineering
  • 19. Eurofins Genomics
  • 20. Eurogentec
  • 21. EVEC
  • 22. Eyetech Pharmaceuticals (Acquired by Valeant Pharmaceuticals)
  • 23. Facible Biodiagnostics
  • 24. Farallon Capital Management
  • 25. Foresite Capital
  • 26. G. N. Tech Venture Investment
  • 27. GC Pharma
  • 28. Gene Link
  • 29. Genomictree
  • 30. Giner
  • 31. GlyTech
  • 32. GNS Healthcare
  • 33. Granzer Regulatory Consulting and Services
  • 34. Guardian Therapeutics
  • 35. Halo-Bio RNAi Therapeutics
  • 36. Hanlim Pharmaceutical
  • 37. Harvard University
  • 38. HB Investment
  • 39. Healios
  • 40. Horizon Discovery
  • 41. IBA Lifesciences
  • 42. iCarbonX
  • 43. ID Ventures
  • 44. Imperial College London
  • 45. Inception 4 (Acquired by IVERIC bio)
  • 46. Insight Partners
  • 47. Institute of Hematology and Transfusion Medicine
  • 48. Integrated DNA Technologies
  • 49. Intermountain Ventures
  • 50. Interoligo
  • 51. IVERIC bio
  • 52. Iwon Medical Foundation
  • 53. Ixaka
  • 54. Janssen
  • 55. Janus Henderson Investors
  • 56. Japan Agency for Medical Research and Development (AMED)
  • 57. Jena Bioscience
  • 58. Juntendo University School of Medicine
  • 59. Keio University School of Medicine
  • 60. King's College London
  • 61. Kiwoom Investment
  • 62. Korea Investment Partners
  • 63. Kreos Capital
  • 64. LC Sciences
  • 65. Leeds Centre for Personalised Medicine and Health
  • 66. LGC
  • 67. LinkBio
  • 68. Logos Capital
  • 69. Lucerna
  • 70. Madryn Asset Management
  • 71. Maravai LifeSciences
  • 72. Maruho
  • 73. Masaryk University
  • 74. Massachusetts General Hospital
  • 75. Medical Innovation Ventures (Mediven®)
  • 76. Medical University of Vienna
  • 77. MeiraGTx
  • 78. Meneldor
  • 79. Merck
  • 80. Metabion
  • 81. Millennium Management
  • 82. Ministry of Science and Innovation (Spain)
  • 83. Mint Diagnostics
  • 84. Mizuho Capital
  • 85. Mologic
  • 86. MultiplexDX
  • 87. nal von minden
  • 88. Nan Fung Life Sciences
  • 89. NanoMosaic
  • 90. National Cancer Center
  • 91. National Center for Tumor Diseases (NCT)
  • 92. National Institutes of General Medical Sciences (NIGMS)
  • 93. National Institutes of Health
  • 94. NEC
  • 95. NEC Solution Innovators
  • 96. Nencki Institute of Experimental Biology
  • 97. NeoNeuro
  • 98. NeoVentures
  • 99. NES Biotechnology
  • 100. NeuraMedy
  • 101. New England Biolabs
  • 102. New York Stem Cell Foundation Research Institute (NYSCF)
  • 103. Nexmos
  • 104. Nitto Avecia
  • 105. NOVAPTECH
  • 106. Novartis
  • 107. Novo Nordisk
  • 108. NOXXON Pharma
  • 109. NVIGEN
  • 110. Nyenburgh Investment Partners (NYIP)
  • 111. Oak BioSciences
  • 112. Osaka University
  • 113. Otsuka Chemical
  • 114. Otsuka Pharmaceutical
  • 115. Oxford University
  • 116. PCL Health
  • 117. Pecic Lab
  • 118. Peking Union Medical College
  • 119. PerkinElmer
  • 120. Pfizer
  • 121. PINOTBIO
  • 122. ProAxsis
  • 123. Profacgen
  • 124. Proteovista
  • 125. Pura Vida Investments
  • 126. Pure Biologics
  • 127. Qualigen Therapeutics
  • 128. Quimigen
  • 129. RayBiotech
  • 130. Redmile Group
  • 131. Regado Biosciences (A Subsidiary of Allergan)
  • 132. Rev1 Ventures
  • 133. Revelation Partners
  • 134. RIBOMIC
  • 135. Ritter Pharmaceuticals
  • 136. Samurai Incubate
  • 137. SB Management (A Subsidiary of SoftBank)
  • 138. SBI Group
  • 139. SBI Pharmaceuticals
  • 140. Seattle Children's Research Institute
  • 141. Seikagaku
  • 142. Sekisui Diagnostics
  • 143. Showa Denko Materials
  • 144. SMBC Venture Capital
  • 145. SM-Sino Technology Investment
  • 146. SomaLogic
  • 147. Suzhou Ribo Life Science
  • 148. Synbio Technologies
  • 149. TAGCyx Biotechnologies
  • 150. Taisho Pharmaceutical
  • 151. Takeda
  • 152. The Ohio State University
  • 153. Tiger Gene
  • 154. Time BioVentures
  • 155. Tobira Therapeutics (Acquired by Allergan)
  • 156. Torres Quevedo Grant
  • 157. TriBiotica
  • 158. TriLink BioTechnologies (acquired by Maravai LifeSciences)
  • 159. Twist Bioscience
  • 160. Ulisse BioMed
  • 161. Univeristy College London
  • 162. University Health Network
  • 163. University of Hong Kong
  • 164. University of Louisville
  • 165. University of Manchester
  • 166. University of Tokyo
  • 167. Uppsala University Hospital
  • 168. UTokyo Innovation Platform
  • 169. ValitaCell
  • 170. Visium Healthcare Partners
  • 171. Vivonics
  • 172. WuXi STA (A Subsidiary of WuXi AppTec)
  • 173. Ziff Capital Healthcare Ventures
目次

Title:
Aptamers:
Therapeutics, Technologies and Services Market, Distribution by Application Area (Therapeutics, Research and Diagnostics), Type of Aptamer (DNA, RNA and Peptide), Target Indication (Geographic Atrophy, Macular Degeneration, Von Willebrand Diseases, Hemophilia A), Route of Administration (Intravitreal, Intravenous, Subcutaneous), Scale of Operation (Small Scale, Medium Scale and Large Scale), Focus Area (Product Development, Product Commercialization, Technology Integration, Technology Utilization and Others), Company Size (Very Small, Small, Mid-sized, Large and Very Large) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2022-2035.

Example Insights:

Overview

Post the approval of the first aptamer-based therapy, Macugen®, by the US Food and Drug Administration (USFDA) in December 2004, there has been a significant increase in the R&D initiatives focused on evaluating the potential of aptamers as theranostic agents. In the following year, the outstanding annual sales (USD 200 million) of the aforementioned product further bolstered the confidence of industry stakeholders in this new therapeutic modality, creating lucrative opportunity for therapy developers. Further, over 100 clinical trials, along with several preclinical studies, have demonstrated the potential of aptamers as a safe and effective treatment modality, owing to their unique characteristics, such as high binding affinity and specificity. Given the various advantages, aptamer-based therapeutics in the current pipeline are targeting a range of therapeutic areas, such as oncological disorders, ophthalmological disorders and metabolomic disorders. It is worth mentioning that, in order to further enhance their performance, aptamers can be linked with various diagnostic agents, using physical or chemical conjugation. Moreover, to ensure the development of more effective therapy candidates, several players have developed novel aptamer-based technologies that can be used for research, drug delivery and diagnostic applications. At present, such technologies are widely being used for pathogen recognition, cancer recognition, monitoring environmental contamination, and as stem cell markers, which can help in both disease prevention and treatment. In addition, post the onset of COVID-19 pandemic, there has been a significant rise in the demand for COVID-19 testing kits, which has prompted several companies to develop aptamer-based diagnostic tools for the detection of SARS-CoV-2. Consequently, to support the various initiatives undertaken by industry players, investments worth over USD 1.3 billion have been reported in the past five years.

Presently, a significant portion of the existing manufacturing capabilities and expertise in this domain belongs to more than 50 contract service providers. Therefore, several researchers and therapy / diagnostic developers prefer to outsource their aptamer manufacturing operations. Given the rise in global disease burden over the past few years, there has been an evident increase in the demand for effective targeted therapies along with novel diagnostic approaches to reduce development timelines and investments. We believe that, with an increase in the number of aptamer-based therapies being developed and subsequent advancement of therapies across various stages of clinical trials, and their eventual commercialization, the opportunities for custom / contract service providers is likely to increase in the foreseen future. Overall, aptamer therapeutics, technologies and services market is poised to witness healthy growth over the next decade, with pioneers in the field likely to benefit from the first-to-market advantage.

Scope of the Report

The "Aptamers: Therapeutics, Technologies and Services Market, Distribution by Application Area (Therapeutics, Research and Diagnostics), Type of Aptamer (DNA, RNA and Peptide), Target Indication (Geographic Atrophy, Macular Degeneration, Von Willebrand Diseases, Hemophilia A), Route of Administration (Intravitreal, Intravenous, Subcutaneous), Scale of Operation (Small Scale, Medium Scale and Large Scale), Focus Area (Product Development, Product Commercialization, Technology Integration, Technology Utilization and Others), Company Size (Very Small, Small, Mid-sized, Large and Very Large) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2022-2035" report features an extensive study of the current market landscape and the likely future potential associated with the aptamer-based therapies, technologies and services market. The study also includes an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field. Amongst other elements, the report features:

  • A detailed overview of the overall market landscape of players engaged in the development of aptamer-based therapeutics, along with information on several relevant parameters, such as year of establishment, company size, type of aptamer (DNA aptamers, RNA aptamers, L-RNA aptamers and peptide aptamers), location of headquarters, phase of development (discovery, pre-clinical, clinical and approved), line of treatment (1st and 2nd line of treatment) , mechanism of action, route of administration (intravenous, intravitreal and subcutaneous) , type of therapy (monotherapy and combinational therapy) , therapeutic area (bleeding disorders, bone disorders, cardiovascular disorders, gastrointestinal disorders, genetic disorders, hematological disorders, immunological disorders, infectious diseases, inflammatory disorders, metabolic disorders, neurological disorders, oncological disorders and ophthalmological disorders) and target indication (geographic atrophy, macular degeneration, stroke, acute stroke, ischemic stroke, multiple myeloma, chronic lymphocytic leukemia, metastatic pancreatic cancer and others) .
  • A detailed overview of the current market landscape of players engaged in the development of aptamer-based technologies, based on several relevant parameters, such as year of establishment, company size, type of aptamer (DNA aptamers, RNA aptamers and peptide aptamers) , location of headquarters, status of development (concept, under development and commercialized) , type of technology used (SELEX, NGS, ELISA and others) , application area (research, diagnostic and therapeutic purposes) , purpose of technology (Characterization, drug discovery, drug development, identification, biomarker discovery, assay, validation and others) , type of analyte (serum, plasma, saliva and others) , therapeutic area (autoimmune disorders, infectious disorders, neurodegenerative disorders, neurological disorders, antibiotic resistance, bone disorders, CNS disorders, genetic disorders, infectious diseases, nephrological disorders, oncological disorders, ophthalmological disorders, oral diseases and psychological disorders) and target indication (amyotrophic lateral sclerosis, breast cancer , colon cancer, dengue virus, liver cancer, prostate cancer, porcine reproductive and respiratory syndrome virus (PRRSv), mycoplasma hyopneumoniae, stomach cancer and others) .
  • A detailed overview of the current market landscape of aptamer-based service providers, along with information on several relevant parameters, such as year of establishment, company size, location of headquarters, type of service provider (contract research organizations, contract manufacturing organizations and third-party service providers) , scale of operation (small, medium and large scale) , area of application (therapeutic, diagnostic and others) , type of technology used (ELISA, NGS, SELEX and others) , type of technology platform (computational and others) , and types of analysis offered (discovery, screening, characterization, synthesis, modification and purification) .
  • A detailed competitiveness analysis of aptamer-based service providers, based on several relevant parameters, such as supplier strength (in terms of years of experience), portfolio strength (in terms of number of services offered) and portfolio diversity (based on scale of operation, area of application, technology used and types of analysis offered) .
  • An insightful competitiveness analysis of aptamer-based technologies, based on supplier strength (in terms of years of experience), and portfolio diversity (based on type of aptamer, status of development, area of application, type of technology used and purpose of technology) .
  • An insightful product competitiveness analysis, benchmarking aptamer-based therapies, based on supplier strength (in terms of years of experience), and portfolio diversity (based on phase of development, line of treatment, type of therapy, route of administration and target indication) .
  • An analysis on the recent developments within the aptamers industry, highlighting information on several partnerships and collaborations that have been established in this domain, during the period 2016-2021.
  • A detailed analysis of various investments made by players engaged in this domain, based on several relevant parameters, such as year of investment, number of funding instances, amount invested and type of funding (venture capital financing, debt financing, grants / awards, initial public offering (IPO)) undertaken by companies engaged in this domain, during the period 2016-2021.
  • An in-depth analysis of academic grants that have been awarded to various research institutes for projects focused on aptamers, based on several parameters, such as year of grant award, amount awarded, type of funding institute center, popular NIH departments, support period, emerging focus area, purpose of grants, grant activity code, local recipients, type of recipient organization study section and type of grant application. Further, the chapter also highlights the popular recipient organizations, (in terms of number of grants and amount awarded) and prominent program officers.
  • A detailed review of close to 390 peer-reviewed, scientific articles related to research on aptamers, based on several parameters, such as year of publication, type of publication, and popular keywords. The chapter also provides information on the top journals, top institutes and top authors (in terms of number of articles published).
  • An in-depth analysis of patents related to aptamer-based therapies and technologies, filed / granted since 2016, based on several relevant parameters, such as publication year, geographical location / patent jurisdiction, legal status, CPC symbols, emerging focus areas, type of applicant and leading players (by number of patents). In addition, it features a patent valuation analysis which evaluates the qualitative and quantitative aspects of the patents.
  • A detailed analysis of completed, ongoing and planned clinical studies, based on several relevant parameters, such as trial registration year, enrolled patient population, trial status, trial phase, type of sponsor / collaborator, patient segment, target therapeutic area, study design, most active players and regional distribution of trials.
  • An analysis of the start-ups (established between 2011-2020; less than 200 employees) engaged in this domain, based on several parameters, such as number of technologies offered, type of aptamer, status of development, area of application, type of technology used and purpose of technology.
  • Elaborate profiles of prominent players (shortlisted based our proprietary scoring criteria) engaged in this domain. Each company profile features a brief overview of the company, along with information on its year of establishment, number of employees, location of headquarters and key executives. It also includes details on their respective product portfolio, recent developments and an informed future outlook.
  • Elaborate profiles of prominent technologies (shortlisted based our proprietary scoring criteria) developed by players engaged in this domain. Each technology profile features a brief overview of the company, along with information on its year of establishment, number of employees, location of headquarters and key members of the executive team. It also includes details on their respective technology portfolio, recent developments and an informed future outlook.
  • An informed estimate of the annual clinical and commercial demand for aptamer-based therapeutics, taking into account the target patient population in ongoing and planned clinical trials focused on aptamer-based therapies, sponsored by both industry and non-industry players.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the aptamer-based therapies, technologies and services market. We have provided an informed estimate of the evolution of the market for the period 2022-2035. Our year-wise projections of the current and future opportunity have further been segmented on the basis of [A] application area (therapeutics, research and diagnostics), [B] type of aptamer (DNA, RNA and peptide), [C] target indication (geographic atrophy, macular degeneration, Von Willebrand diseases, hemophilia A), [D] route of administration (intravitreal, intravenous, subcutaneous), [E] scale of operation (clinical and commercial), [F] focus area (product development, product commercialization, technology integration, technology utilization and others), [G] company size (very small, small, mid-sized, large and very large) and [H] key geographical regions (North America, Europe, Asia-Pacific And Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the market's evolution.

Key Questions Answered:

  • Who are the key players engaged in the development of aptamer-based therapeutics and technologies?
  • Which are the key drugs being evaluated across early and late stages of development?
  • Which companies are actively involved providing aptamer-based services?
  • What is the evolving trend of publications focused on aptamer-based therapeutics and technologies?
  • What type of partnership models are commonly adopted by industry stakeholders?
  • Who are the key investors in this domain?
  • Which companies are actively filing patents to drive innovation in this niche segment?
  • What are the different initiatives undertaken by start-up players for the development of aptamer-based technologies in the recent past?
  • How is the current and future opportunity likely to be distributed across key market segments?

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of aptamers market and its likely evolution in the short to mid-long term.

Chapter 3 provides a general overview of the aptamers. In addition, it features information on the historical timeline and evolution of SELEX, processes involved in the selection of aptamers. It also features an elaborate description of types of aptamers and need for aptamer modifications. Further, it highlights the various applications of aptamers and opportunities associated within the domain.

Chapter 4 provides a detailed overview of the overall market landscape of players engaged in the development of aptamer-based therapeutics, along with information on several relevant parameters, such as year of establishment, company size, type of aptamer (DNA aptamers, RNA aptamers, L-RNA aptamers and peptide aptamers) , location of headquarters, phase of development (discovery, pre-clinical, clinical and approved) , line of treatment (1st and 2nd line of treatment) , mechanism of action, route of administration (intravenous, intravitreal and subcutaneous) , type of therapy (monotherapy and combinational therapy) , therapeutic area (bleeding disorders, bone disorders, cardiovascular disorders, gastrointestinal disorders, genetic disorders, hematological disorders, immunological disorders, infectious diseases, inflammatory disorders, metabolic disorders, neurological disorders, oncological disorders and ophthalmological disorders) and target indication (geographic atrophy, macular degeneration, stroke, acute stroke, ischemic stroke, multiple myeloma, chronic lymphocytic leukemia, metastatic pancreatic cancer and others) .

Chapter 5 provides a detailed overview of the current market landscape of players engaged in the development of aptamer-based technologies, based on several relevant parameters, such as year of establishment, company size, type of aptamer (DNA aptamers, RNA aptamers and peptide aptamers) , location of headquarters, status of development (concept, under development and commercialized) , type of technology used (SELEX, NGS, ELISA and others) , application area (research, diagnostic and therapeutic purposes) , purpose of technology (Characterization, drug discovery, drug development, identification, biomarker discovery, assay, validation and others) , type of analyte (serum, plasma, saliva and others) , therapeutic area (autoimmune disorders, infectious disorders, neurodegenerative disorders, neurological disorders, antibiotic resistance, bone disorders, CNS disorders, genetic disorders, infectious diseases, nephrological disorders, oncological disorders, ophthalmological disorders, oral diseases and psychological disorders) and target indication (amyotrophic lateral sclerosis, breast cancer, colon cancer, dengue virus, liver cancer, prostate cancer, porcine reproductive and respiratory syndrome virus (PRRSv), mycoplasma hyopneumoniae, stomach cancer and others) .

Chapter 6 provides a detailed overview of the current market landscape of aptamer-based service providers, along with information on several relevant parameters, such as year of establishment, company size, location of headquarters, type of service provider (contract research organizations, contract manufacturing organizations and third-party service providers) , scale of operation (small, medium and large scale) , area of application (therapeutic, diagnostic and others) , type of technology used (ELISA, NGS, SELEX and others) , type of technology platform (computational and others) , and types of analysis offered (discovery, screening, characterization, synthesis, modification and purification) .

Chapter 7 provides an insightful competitiveness analysis of aptamer-based service providers, based on several relevant parameters, such as supplier strength (in terms of years of experience), portfolio strength (in terms of number of services offered) and portfolio diversity (based on scale of operation, area of application, technology used and types of analysis offered) .

Chapter 8 provides an insightful competitiveness analysis of aptamer-based technologies, based on supplier strength (in terms of years of experience), and portfolio diversity (based on type of aptamer, status of development, area of application, type of technology used and purpose of technology) .

Chapter 9 provides an insightful product competitiveness analysis, benchmarking aptamer-based therapies, based on supplier strength (in terms of years of experience), and portfolio diversity (based on phase of development, line of treatment, type of therapy, route of administration and target indication) .

Chapter 10 features an analysis on the recent developments within the aptamers industry, highlighting information on several partnerships and collaborations that have been established in this domain, during the period 2016-2021.

Chapter 11 features a detailed analysis of various investments made by players engaged in this domain, based on several relevant parameters, such as year of investment, number of funding instances, amount invested and type of funding (venture capital financing, debt financing, grants / awards, initial public offering (IPO) ) undertaken by companies engaged in this domain, during the period 2016-2021.

Chapter 12 consists of an analysis of academic grants that have been awarded to various research institutes for projects focused on aptamers, based on several parameters, such as year of grant award, amount awarded, type of funding institute center, popular NIH departments, support period, emerging focus area, purpose of grants, grant activity code, local recipients, type of recipient organization study section and type of grant application. Further, the chapter also highlights the popular recipient organizations, (in terms of number of grants and amount awarded) and prominent program officers.

Chapter 13 provides a detailed review of close to 390 peer-reviewed, scientific articles related to research on aptamers, based on several parameters, such as year of publication, type of publication, and popular keywords. The chapter also provides information on the top journals, top institutes and top authors (in terms of number of articles published).

Chapter 14 consists of an analysis of patents related to aptamer-based therapies and technologies, filed / granted since 2016, based on several relevant parameters, such as publication year, geographical location / patent jurisdiction, legal status, CPC symbols, emerging focus areas, type of applicant and leading players (by number of patents). In addition, it features a patent valuation analysis which evaluates the qualitative and quantitative aspects of the patents.

Chapter 15 provides a detailed analysis of completed, ongoing and planned clinical studies, based on several relevant parameters, such as trial registration year, enrolled patient population, trial status, trial phase, type of sponsor / collaborator, patient segment, target therapeutic area, study design, most active players and regional distribution of trials.

Chapter 16 provides an analysis of the start-ups (established between 2011-2020; less than 200 employees) engaged in this domain, based on several parameters, such as number of technologies offered, type of aptamer, status of development, area of application, type of technology used and purpose of technology.

Chapter 17 includes elaborate profiles of prominent players (shortlisted based our proprietary scoring criteria) engaged in this domain. Each company profile features a brief overview of the company, along with information on its year of establishment, number of employees, location of headquarters and key executives. It also includes details on their respective product portfolio, recent developments and an informed future outlook.

Chapter 18 includes elaborate profiles of prominent technologies (shortlisted based our proprietary scoring criteria) developed by players engaged in this domain. Each technology profile features a brief overview of the company, along with information on its year of establishment, number of employees, location of headquarters and key members of the executive team. It also includes details on their respective technology portfolio, recent developments and an informed future outlook.

Chapter 19 presents and informed estimate of the annual clinical and commercial demand for aptamer-based therapeutics, taking into account the target patient population in ongoing and planned clinical trials focused on aptamer-based therapies, sponsored by both industry and non-industry players.

Chapter 20 presents an insightful market forecast analysis, highlighting the likely growth of aptamers market, till 2032. In order to provide a detailed future outlook, our projections have been segmented across different segments on the basis of [A] application area (therapeutics, research and diagnostics), [B] type of aptamer (DNA, RNA and peptide), [C] target indications (geographic atrophy, macular degeneration, Von Willebrand diseases, hemophilia A), [D] route of administration (intravitreal, intravenous, subcutaneous), [E] scale of operation (clinical and commercial), [F] focus area (product development, product commercialization, technology integration, technology utilization and others), [G] company size (very small, small, mid-sized, large and very large) and [H] key geographical regions (North America, Europe, Asia-Pacific And Rest of the World).

Chapter 21 presents an insightful discussion on the views presented by various industry experts present across the globe, on YouTube. The summary of insights provided by each expert is discussed across focus area, current industry status / challenges and future outlook

Chapter 22 is a summary of the overall report, presenting the insights on the contemporary market trends and the likely evolution of the aptamers market.

Chapter 23 is an appendix that contains tabulated data and numbers for all the figures in the report.

Chapter 24 is an appendix that provides the list of companies and organizations mentioned in the report.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Key Questions Answered
  • 1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Introduction to Aptamers
    • 3.2.1. Systematic Evolution of Ligands by Exponential Enrichment (SELEX)
  • 3.3. Types of Aptamers
    • 3.3.1. DNA Aptamers
    • 3.3.2. RNA Aptamers
    • 3.3.3. Peptide Aptamers
    • 3.3.4. XNA Aptamers
  • 3.4. Need for Aptamer Modifications
  • 3.5. Advantages of Aptamers
  • 3.6. Limitations of Aptamers
  • 3.7. Applications of Aptamers
  • 3.8. Future Anticipated Trends and Opportunities

4. MARKET OVERVIEW: THERAPEUTIC CANDIDATES

  • 4.1. Chapter Overview
  • 4.2. Aptamer-based Therapeutics: Market Landscape
    • 4.2.1. Analysis by Type of Aptamer
    • 4.2.2. Analysis by Phase of Development
    • 4.2.3. Analysis by Line of Treatment
    • 4.2.4. Analysis by Route of Administration
    • 4.2.5. Analysis by Mechanism of Action
    • 4.2.6. Analysis by Target Indication
    • 4.2.7. Analysis by Therapeutic Area
    • 4.2.8. Analysis by Type of Therapy
  • 4.3. Aptamer-based Therapeutics: Developer Landscape
    • 4.3.1. Analysis by Year of Establishment
    • 4.3.2. Analysis by Company Size
    • 4.3.3. Analysis by Location of Headquarters
    • 4.3.4. Analysis by Company Size and Location of Headquarters
    • 4.3.5. Most Active Players: Analysis by Number of Therapies

5. MARKET OVERVIEW: TECHNOLOGY PROVIDERS

  • 5.1. Chapter Overview
  • 5.2. Aptamer-based Technologies: Market Landscape
    • 5.2.1. Analysis by Type of Aptamer
    • 5.2.2. Analysis by Status of Development
    • 5.2.3. Analysis by Application Area
    • 5.2.4. Analysis by Type of Technology Used
    • 5.2.5. Analysis by Purpose of Technology
    • 5.2.6. Analysis by Type of Analyte
    • 5.2.7. Analysis by Therapeutic Area
    • 5.2.8. Analysis by Target Indication
    • 5.2.9. Analysis by Application Area, Purpose of Technology and Region
  • 5.3. Aptamer-based Technologies: Developer Landscape
    • 5.3.1. Analysis by Year of Establishment
    • 5.3.2. Analysis by Company Size
    • 5.3.3. Analysis by Location of Headquarters
    • 5.3.4. Analysis by Company Size and Location of Headquarters

6. MARKET OVERVIEW: SERVICE PROVIDERS

  • 6.1. Chapter Overview
  • 6.2. Aptamer-based Service Providers: Market Landscape
    • 6.2.1. Analysis by Type of Service Provider
    • 6.2.2. Analysis by Scale of Operation
    • 6.2.3. Analysis by Application Area
    • 6.2.4. Analysis by Type of Technology Used
    • 6.2.5. Analysis by Type of Technology Platform
    • 6.2.6. Analysis by Types of Analysis Offered
    • 6.2.7. Analysis by Type of Service Provider, Type of Analysis Offered and Region
  • 6.3. Aptamer-based Service Providers: Developer Landscape
    • 6.3.1. Analysis by Year of Establishment
    • 6.3.2. Analysis by Company Size
    • 6.3.3. Analysis by Location of Headquarters
    • 6.3.4. Analysis by Company Size and Location of Headquarters

7. COMPANY COMPETITIVENESS ANALYSIS

  • 7.1. Chapter Overview
  • 7.2. Methodology and Key Parameters
  • 7.3. Aptamer-based Service Providers: Company Competitiveness Analysis
    • 7.3.1. Very Small Companies (Peer Group 1)
    • 7.3.2. Small Companies (Peer Group 2)
    • 7.3.3. Mid-sized Companies (Peer Group 3)
    • 7.3.4. Large Companies (Peer Group 4)
    • 7.3.5. Very Large Companies (Peer Group 5)

8. TECHNOLOGY COMPETITIVENESS ANALYSIS

  • 8.1. Chapter Overview
  • 8.2. Methodology and Key Parameters
  • 8.3. Aptamer-based Technology Providers
    • 8.3.1. Very Small Companies (Peer Group 1)
    • 8.3.2. Small Companies (Peer Group 2)
    • 8.3.3. Mid-sized Companies (Peer Group 3)
    • 8.3.4. Large Companies (Peer Group 4)
    • 8.3.5. Very Large Companies (Peer Group 5)

9. PRODUCT COMPETITIVENESS ANALYSIS

  • 9.1. Chapter Overview
  • 9.2. Methodology and Key Parameters
  • 9.3. Aptamer-based Therapeutics
    • 9.3.1. Very Small Companies (Peer Group 1)
    • 9.3.2. Small Companies (Peer Group 2)
    • 9.3.3. Mid-sized Companies (Peer Group 3)
    • 9.3.4. Large Companies (Peer Group 4)
    • 9.3.5. Very Large Companies (Peer Group 5)

10. PARTNERSHIPS AND COLLABORATIONS

  • 10.1. Aptamer Therapeutics, Technologies and Service Providers: List of Partnerships and Collaborations
  • 10.1.1 Analysis by Year, 2016-2021
    • 10.1.2. Analysis by Type of Partnership
    • 10.1.3. Analysis by Year and Type of Partnership
    • 10.1.4. Analysis by Type of Partner
    • 10.1.5. Analysis by Year and Type of Partner
    • 10.1.6. Analysis by Type of Partnership and Type of Partner
    • 10.1.7. Analysis by Focus Area
    • 10.1.8. Most Active Players: Analysis by Number of Partnerships
    • 10.1.9. Analysis by Region (Continent-wise)
  • 10.1.9.1 Intercontinental and Intracontinental Agreements
    • 10.1.10. Analysis by Region (Country-wise)
  • 10.1.9.1 Local and International Agreements

11. FUNDING AND INVESTMENTS

  • 11.1. Aptamer Therapeutics, Technologies and Service Providers: List of Funding and Investments
    • 11.1.1. Cumulative Analysis of Instances by Year, 2016-2021
    • 11.1.2. Analysis of Instances by Type of Funding
    • 11.1.3. Analysis of Instances by Year and Type of Funding, 2016-2021
    • 11.1.4. Cumulative Analysis of Amount Invested by Year, 2016-2021
    • 11.1.5. Analysis of Amount Invested by Type of Funding
    • 11.1.6. Analysis of Type of Funding and Amount Invested by Year, 2016-2021
    • 11.1.7. Analysis of Instances by Region
    • 11.1.8. Analysis of Total Amount Invested by Region
    • 11.1.9. Most Active Players: Analysis by Number of Instances
    • 11.1.10. Most Active Players: Analysis by Amount Raised
    • 11.1.11. Most Active Investors: Analysis by Number of Instances

12. GRANTS ANALYSIS

  • 12.1. Aptamer Therapeutics, Technologies and Service Providers: List of Academic Grants
    • 12.1.1. Cumulative Year-wise Trend of Gransts, 2016-2021
    • 12.1.2. Analysis by Grant Amount
    • 12.1.3. Analysis by Activity Codes
    • 12.1.4. Analysis by Support Period
    • 12.1.5. Analysis by Purpose of Grant
    • 12.1.6. Analysis by Type of Grant
    • 12.1.7. Analysis by Funding Institute and Support Period
    • 12.1.8. Analysis by Type of Organization
    • 12.1.9. Most Popular Recipient Organization: Analysis by Number of Instances
    • 12.1.10. Most Popular Recipient Organization: Analysis by Amount Granted
    • 12.1.11. Most Popular Recipient Organization: Distribution in US
    • 12.1.12. Prominent Program Officers: Analysis by Number of Grants
    • 12.1.13. Analysis by Study Section
    • 12.1.14. Analysis by Most Popular Department
    • 12.1.15. Word Cloud of Popular NIH Spending Categories

13. PUBLICATION ANALYSIS

  • 13.1. Aptamer Therapeutics, Technologies and Service Providers: List of Publications
    • 13.1.1. Analysis by Quarterly Trend of Publications (2021)
    • 13.1.2. Analysis by Type of Publication
    • 13.1.3. Analysis by Most Popular Journal
    • 13.1.4. Analysis by Most Popular Author
    • 13.1.5. Analysis by Most Popular Publisher
    • 13.1.6. Analysis by Most Popular Copyright Holder
    • 13.1.7. Analysis by Most Popular Keywords
    • 13.1.8. Analysis by Affiliation
    • 13.1.9. Analysis by Affiliation and Geography
    • 13.1.10. Analysis by Funding Institutes

14. PATENT ANALYSIS

  • 14.1. Chapter Overview
  • 14.2. Scope and Methodology
  • 14.3. Aptamer Therapeutics, Technologies and Service Providers: Patent Analysis
    • 14.3.1. Analysis by Type of Patent
    • 14.3.2. Analysis by Granted Patents
    • 14.3.3. Analysis by Publication Year
    • 14.3.4. Year-wise Trend of Filed Patent Applications
    • 14.3.5. Analysis by Issuing Authority
    • 14.3.6. Analysis by Patent Focus
    • 14.3.7. Analysis by Patent Age
    • 14.3.8. Analysis by CPC Symbols
    • 14.3.9. Analysis by Type of Applicant
    • 14.3.10. Leading Players: Analysis by Number of Patents

15. CLINICAL TRIAL ANALYSIS

  • 15.1. Chapter Overview
  • 15.2. Scope and Methodology
  • 15.3. Aptamer-based Therapeutics: List of Clinical Trials
    • 15.3.1. Analysis by Trial Status
    • 15.3.2. Analysis by Trial Registration Year
    • 15.3.3. Analysis by Trial Status and Trial Registration Year
    • 15.3.4. Analysis by Number of Patients Enrolled and Phase of Development
    • 15.3.5. Analysis by Type of Sponsor
    • 15.3.6. Analysis by Target Patient Group
    • 15.3.7. Analysis by Study Type
    • 15.3.8. Analysis by Type of Masking
    • 15.3.9. Analysis by Type of Interventional Model
    • 15.3.10. Analysis by Primary Purpose of Trial
    • 15.3.11. Analysis of Enrolled Patient Population by Geography

16. START-UP HEALTH INDEXING

  • 16.1. START-UP HEALTH INDEXING
  • 16.2. Start-ups Focused on Aptamer-based Technology Providers
  • 16.3. Methodology and Key Parameters
  • 16.4.1 Analysis by Number of Technologies
    • 16.2.2. Analysis by Type of Aptamer
    • 16.2.3. Analysis by Status of Development
    • 16.2.4. Analysis by Area of Application
    • 16.2.5. Analysis by Type of Bioanalytical Technology Used
    • 16.2.6. Analysis by Technology Application Area
    • 16.2.7. Analysis by Patent Count
    • 16.2.8. Start-ups Health Indexing: Roots Analysis Perspective

17. COMPANY PROFILES

  • 17.1. Chapter Overview
  • 17.2. Ajinomoto Bio-Pharma Services
    • 17.2.1. Company Overview
    • 17.2.2. Financial Information
    • 17.2.3. Service Portfolio
    • 17.2.4. Recent Developments and Future Outlook
  • 17.3. BioSpring
    • 17.3.1. Company Overview
    • 17.3.2. Service Portfolio
    • 17.3.3. Recent Developments and Future Outlook
  • 17.4. CliniSciences
    • 17.4.1. Company Overview
    • 17.4.2. Service Portfolio
    • 17.4.3. Recent Developments and Future Outlook
  • 17.5. New England Biolabs
    • 17.5.1. Company Overview
    • 17.5.2. Product Portfolio
    • 17.5.3. Recent Developments and Future Outlook
  • 17.6. LGC Biosearch Technologies
    • 17.6.1. Company Overview
    • 17.6.2. Financial Information
    • 17.6.3. Product Portfolio
    • 17.6.4. Recent Developments and Future Outlook
  • 17.7. Nitto Denko Avecia
    • 17.7.1. Company Overview
    • 17.7.2. Service Portfolio
    • 17.7.3. Manufacturing Facilities and Capabilities
    • 17.7.4. Recent Developments and Future Outlook
  • 17.8. CMIC Group
    • 17.8.1. Company Overview
    • 17.8.2. Product Portfolio
    • 17.8.3. Recent Developments and Future Outlook

18. TECHNOLOGY PROFILES

  • 18.1. Chapter Overview
  • 18.2. SomaLogic
    • 18.2.1. Company Overview
    • 18.2.2. Technology Overview
    • 18.2.3. SomaScan
    • 18.2.4. Recent Developments and Future Outlook
  • 18.3. NOXXON Pharma
    • 18.3.1. Company Overview
    • 18.3.2. Technology Overview
    • 18.3.3. Recent Developments and Future Outlook
  • 18.4. RIBOMIC
    • 18.4.1. Company Overview
    • 18.4.2. Financial Information
    • 18.4.3. Technology Overview
    • 18.4.4. Recent Developments and Future Outlook
  • 18.5. Halo-Bio RNAi Therapeutics
    • 18.5.1. Company Overview
    • 18.5.2. Technology Overview
    • 18.5.3. Recent Developments and Future Outlook
  • 18.6. NeuroNeuro
    • 18.6.1. Company Overview
    • 18.6.2. Technology Overview
    • 18.6.3. Aptamarkers
    • 18.6.4. Recent Developments and Future Outlook

19. DEMAND ANALYSIS

  • 19.1. Chapter Overview
  • 19.2. Scope and Methodology
  • 19.3. Global Demand for Aptamers
  • 19.4. Analysis by Scale of Operation
    • 19.4.1. Clinical Demand for Aptamers
    • 19.4.2. Commercial Demand for Aptamers
  • 19.5. Analysis by Region
    • 19.5.1. Demand for Aptamers in North America
    • 19.5.2. Demand for Aptamers in Europe
    • 19.5.3. Demand for Aptamers in Asia-Pacific

20. MARKET FORECAST AND OPPORTUNITY ANALYSIS

  • 20.1. Chapter Overview
  • 20.2. Forecast Methodology
  • 20.3. Global Aptamer Therapeutics, Technologies and Services Market, 2022-2035
  • 20.4. Aptamer Therapeutics Market, 2022-2035
    • 20.4.1. Aptamer Therapeutics Market: Analysis by Type of Aptamer, 2022-2035
      • 20.4.1.1. Aptamer Therapeutics Market for DNA Aptamers, 2022-2035
      • 20.4.1.2. Aptamer Therapeutics Market for RNA Aptamers, 2022-2035
      • 20.4.1.3. Aptamer Therapeutics Market for L-RNA Aptamers, 2022-2035
    • 20.4.2. Aptamer Therapeutics Market: Analysis by Target Indication, 2022-2035
      • 20.4.2.1. Aptamer Therapeutics Market for Brain Cancer, 2022-2035
      • 20.4.2.2. Aptamer Therapeutics Market for Geographic Atrophy, 2022-2035
      • 20.4.2.3. Aptamer Therapeutics Market for Hemophilia A, 2022-2035
      • 20.4.2.4. Aptamer Therapeutics Market for Macular Degeneration, 2022-2035
      • 20.4.2.5. Aptamer Therapeutics Market for Pancreatic Cancer, 2022-2035
      • 20.4.2.6. Aptamer Therapeutics Market for Von Willebrand Diseases, 2022-2035
    • 20.4.3. Aptamer Therapeutics Market: Analysis by Route of Administration, 2022-2035
      • 20.4.3.1. Aptamer Therapeutics Market for Intravenous Route, 2022-2035
      • 20.4.3.2. Aptamer Therapeutics Market for Intravitreal Route, 2022-2035
      • 20.4.3.3. Aptamer Therapeutics Market for Subcutaneous Route, 2022-2035
    • 20.4.4. Aptamer Therapeutics Market: Analysis by Geography, 2022-2035
      • 20.4.4.1. Aptamer Therapeutics Market in North America, 2022-2035
      • 20.4.4.2. Aptamer Therapeutics Market in Europe, 2022-2035
      • 20.4.4.3. Aptamer Therapeutics Market in Asia-Pacific, 2022-2035
      • 20.4.4.4. Aptamer Therapeutics Market in Rest of the World, 2022-2035
    • 20.4.5. Drug-wise Sales Forecast
      • 20.4.5.1. Zimura (Iveric Bio)
        • 20.4.5.1.1. Target Patient Population
        • 20.4.5.1.2. Value Creation Analysis
      • 20.4.5.2. NOX-A12 (NOXXON Pharma)
        • 20.4.5.2.1. Target Patient Population
        • 20.4.5.2.2. Value Creation Analysis
      • 20.4.5.3. BT 200 (Guardian therapeutics)
        • 20.4.5.3.1. Target Patient Population
        • 20.4.5.3.2. Value Creation Analysis
      • 20.4.5.4. BC007 (Berlin Cures)
        • 20.4.5.4.1. Target Patient Population
        • 20.4.5.4.2. Value Creation Analysis
  • 20.5. Aptamer Technologies Market, 2022-2035
    • 20.5.1. Aptamer Technologies Market: Analysis by Focus Area, 2022-2035
      • 20.5.1.1. Aptamer Therapeutics Market for Product Development Initiatives, 2022-2035
      • 20.5.1.2. Aptamer Therapeutics Market for Product Commercialization Initiatives, 2022-2035
      • 20.5.1.3. Aptamer Therapeutics Market for Technology Integration Initiatives, 2022-2035
      • 20.5.1.4. Aptamer Therapeutics Market for Technology Utilization Initiatives, 2022-2035
      • 20.5.1.5. Aptamer Therapeutics Market for Other Initiatives, 2022-2035
    • 20.5.2. Aptamer Technologies Market: Analysis by Company Size, 2022-2035
      • 20.5.1.1. Aptamer Therapeutics Market for Very Small Companies, 2022-2035
      • 20.5.1.2. Aptamer Therapeutics Market for Small Companies, 2022-2035
      • 20.5.1.3. Aptamer Therapeutics Market for Mid-sized Companies, 2022-2035
      • 20.5.1.4. Aptamer Therapeutics Market for Large Companies, 2022-2035
      • 20.5.1.5. Aptamer Therapeutics Market for Very Large Companies, 2022-2035
    • 20.5.3. Aptamer Technologies Market: Analysis by Geography, 2022-2035
      • 20.5.3.1. Aptamer Technologies Market in North America, 2022-2035
      • 20.5.3.2. Aptamer Technologies Market in Europe, 2022-2035
      • 20.5.3.3. Aptamer Technologies Market in Asia-Pacific, 2022-2035
  • 20.6. Aptamer Services Market, 2022-2035
    • 20.6.1. Aptamer Services Market: Analysis by Scale of Operation, 2022-2035
      • 20.6.1.1. Aptamer Services Market for Small Scale Operations, 2022-2035
      • 20.6.1.2. Aptamer Services Market for Medium-Scale Operations, 2022-2035
      • 20.6.1.3. Aptamer Services Market for Large Scale Operations, 2022-2035
    • 20.6.2. Aptamer Technologies Market: Analysis by Geography, 2022-2035
      • 20.6.2.1. Aptamer Technologies Market in North America, 2022-2035
      • 20.6.2.2. Aptamer Technologies Market in Europe, 2022-2035
      • 20.6.2.3. Aptamer Technologies Market in Asia-Pacific, 2022-2035

21. CONCLUSION

22. APPENDIX I: TABULATED DATA

23. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS